BRIAN SCHLESINGER: Open Payments
NPI 1013018944 · PALMDALE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$625 in 24 payments from 10 companies in 2025. Trend: 2023 $396 · 2024 $577 · 2025 $625
Food & beverage: $625
| Company | Payments | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | 13 | $349 |
| ABBVIE INC. | 2 | $48 |
| AstraZeneca Pharmaceuticals LP | 2 | $48 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $34 |
| Lilly USA, LLC | 1 | $30 |
| SANOFI-AVENTIS U.S. LLC | 1 | $26 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Novo Nordisk Inc | 1 | $23 |
| ALK-Abello, Inc | 1 | $23 |
| GlaxoSmithKline, LLC. | 1 | $21 |
Products named: JARDIANCE, VRAYLAR, CAPLYTA, MOUNJARO, BREZTRI, TZIELD, REXULTI, Odactra.
Industry payments across CA — which companies pay providers there.
